RGC News

After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and nine SPACs submitting initial filings.   Italian drug container supplier Stevanato Group (STVN)...read more

Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and autism, raised $22 million by offering 2.3 million shares at $9.50, within the range of $8.50 to $10.50. At pricing, the Hong Kong, China-based company commands a market value of $120 million. Regencell is focused on the researching herb-based traditional Chinese medicine ...read more

Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, announced terms for its IPO on Friday. The Hong Kong, China-based company plans to raise $22 million by offering 2.3 million shares at a price range of $8.50 to $10.50. At the midpoint of the proposed range, Regencell Bioscience Holdings would command a fully...read more

Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, filed on Monday with the SEC to raise up to $18 million in an initial public offering. Regencell is focused on the research, development, and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration,...read more